Regenxbio was weeks away from refiling its gene therapy for Hunter syndrome. Then a brain tumor in a related program triggered an FDA clinical hold, adding to a mounting safety crisis across the AAV gene therapy field.
The Gene Therapy That Hit a Wall
Imagine you've been building a house for years. The foundation is poured, the walls are up, and you're about to get your certificate of occupancy. Then the inspector finds a crack in the foundation and tells you to stop everything.
That's roughly where Regenxbio finds itself right now. The company was on track to refile its application for RGX-121 (branded NAVSUNLI), a one-time gene therapy for MPS II, also known as Hunter syndrome. The FDA had signaled that existing data could support accelerated approval, and Regenxbio was planning to resubmit in Q3 2026. Then the agency put the brakes on.
A clinical hold, the FDA's version of a red card, has complicated Regenxbio's path to market once again. And the reason behind it should worry anyone watching the gene therapy space closely.
A Tumor That Changed Everything
The trouble started with a sibling program called RGX-111, Regenxbio's gene therapy for Hurler syndrome (MPS I). During long-term follow-up of a Phase I/II study, doctors found a single CNS tumor in the brain of a child who had been treated with the therapy.
Preliminary analysis pointed to something gene therapy developers dread: an AAV vector genome integration event linked to overexpression of a gene called PLAG1. In plain English, the viral vector used to deliver the therapy may have inserted itself into the patient's DNA in a way that triggered abnormal cell growth. Think of it like a software update that accidentally rewrites a critical line of code, except the code controls whether cells grow out of control.
Regenxbio has said causality hasn't been established. No similar tumors have been found in other patients across either program. But the FDA wasn't taking chances. Because RGX-111 and RGX-121 share similar designs, patient populations, and risk profiles, the agency slapped a clinical hold on both.
A Regulatory Saga Years in the Making
To understand why this stings so badly, you need to know what Regenxbio has already been through with RGX-121.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The company submitted its BLA (the formal application for FDA approval) in March 2025, and the FDA accepted it in May 2025. The FDA granted Priority Review, setting a decision date for November 2025. That date got pushed to February 2026 after the agency wanted to review additional long-term clinical data. Then, in February 2026, the FDA issued a Complete Response Letter (CRL), which is the regulatory equivalent of "thanks, but no."
The rejection wasn't about safety at the time. The FDA raised questions about how the target patient population was defined, whether the external control group was comparable, and whether the biomarker Regenxbio used as a surrogate endpoint actually predicts real clinical benefit.
After the CRL, things seemed to be looking up. Regenxbio and the FDA aligned on a Type A meeting to discuss the path forward. The agency said no additional studies were required and that it would review existing longer-term data on an expedited basis. A Q3 2026 resubmission looked achievable.
Then the clinical hold hit, and the timeline crumbled.
Gene Therapy's Growing Safety Cloud
Regenxbio isn't alone in facing this kind of scrutiny. The FDA has been tightening the screws on AAV-based gene therapies across the board, and the data explains why.
One analysis found that 15 of 33 total clinical holds in the gene therapy space involved AAV-based programs. Of those AAV holds, a striking 73% were triggered by adverse events or patient deaths. This isn't a manufacturing quality problem anymore; it's a clinical safety surveillance problem.
The most dramatic example this cycle has been Sarepta's ELEVIDYS, where the FDA reported three fatal cases of acute liver failure tied to AAVrh74-based therapies. The agency placed related clinical trials on hold, suspended distribution, restricted use to ambulatory patients, and even revoked Sarepta's platform technology designation. That last move was a shot across the bow of the entire field, signaling that the FDA views AAV safety risks as potentially systemic rather than product-specific.
For developers, the new reality means more conservative dose selection, stricter limits on which patients can enroll, enhanced liver monitoring, and much longer follow-up periods. The Regenxbio brain tumor case adds delayed oncogenic risk to the growing list of concerns the FDA is watching.
What Regenxbio Has Left
The company isn't a one-trick pony. Its pipeline, built on a proprietary AAV platform called NAV Technology, spans retinal disease, neurodegenerative conditions, and muscular dystrophy.
The crown jewel is ABBV-RGX-314, a gene therapy for wet age-related macular degeneration (wet AMD) being developed with AbbVie. If approved, it would be the first gene therapy for chronic retinal diseases, replacing the burden of repeated anti-VEGF eye injections with a single treatment. Regulatory submissions were expected between late 2025 and the first half of 2026.
Regenxbio also has RGX-202 for Duchenne muscular dystrophy, which the company says is the only microdystrophin gene therapy candidate that includes a specific protein segment called the CT domain. And RGX-121 itself remains the only potential one-time gene therapy for MPS II, a powerful orphan disease position if the regulatory fog ever clears.
Wall Street Is Patient, for Now
Analysts haven't abandoned ship. The consensus rating remained a "Moderate Buy" as of early August 2026, with roughly 9 to 10 buy ratings, a few holds, and only one sell. But targets got trimmed: H.C. Wainwright, for instance, cut its price target from $26 to $23 while keeping a Buy rating.
The range of targets tells you how uncertain things are. The low end sits around $10; the high end stretches to $50. That's not a consensus, it's a Rorschach test. Bulls see a diversified pipeline with multiple shots on goal. Bears see a cash-burning clinical-stage biotech with binary regulatory outcomes and real dilution risk.
Regenxbio's recent quarterly earnings beat estimates on both EPS and revenue, but the company is still expected to post a full-year loss with negative margins. For a company that needs regulatory wins to survive, every delay is another quarter of cash burn.
The Bigger Picture
Regenxbio's story is a microcosm of the entire AAV gene therapy field in 2026. The science is breathtaking: the idea that you can treat devastating genetic diseases with a single dose feels like something out of science fiction. But the safety signals keep piling up, and the FDA is responding accordingly.
The question isn't whether gene therapy works. It's whether the field can prove it's safe enough over years and decades, not just months. For Regenxbio, the answer to that question determines whether RGX-121 ever reaches the kids who need it most.
Funding & Financings4 min read
A Heart Drug Startup Just Raised $382M on Day One. Wall Street Noticed.
A cardiac drug startup that didn't exist two years ago just raised $440 million in its Nasdaq debut. Braveheart Bio's blockbuster IPO headlined a billion-dollar week for biotech, and it all rides on a single heart drug.
